Published in ACS Chem Neurosci on March 30, 2015
Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model. Biochim Biophys Acta (2016) 0.79
Amyloid-β and Astrocytes Interplay in Amyloid-β Related Disorders. Int J Mol Sci (2016) 0.76
One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug. Front Neurosci (2016) 0.75
Transporters as Drug Targets in Neurological Diseases. Clin Pharmacol Ther (2016) 0.75
Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 19.19
Preparation of isolated rat liver cells. Methods Cell Biol (1976) 17.96
Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA (1989) 8.36
The molecular pathology of Alzheimer's disease. Neuron (1991) 8.21
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology (1998) 7.27
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 5.07
LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron (2004) 4.29
Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci (2005) 3.84
Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov (2010) 3.48
Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci (1999) 3.16
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 2.81
Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med (2012) 2.77
A hundred years of Alzheimer's disease research. Neuron (2006) 2.76
Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci (2000) 2.58
Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA (1994) 2.18
Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics (2002) 1.75
Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat Med (2000) 1.53
The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc Natl Acad Sci U S A (1997) 1.53
Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol (1999) 1.45
MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol (2007) 1.45
The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2004) 1.42
Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.32
Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res (2006) 1.28
Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A (2012) 1.27
Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience (2000) 1.26
Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol Neurodegener (2006) 1.23
Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol (2010) 1.17
Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther (1996) 1.17
Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci Res (2006) 1.11
The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp Brain Res (2000) 1.07
Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease. J Alzheimers Dis (2013) 1.07
Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One (2011) 1.06
Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J Alzheimers Dis (2012) 1.04
Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem (2010) 1.04
Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Neuropharmacology (2014) 1.03
Olive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studies. ACS Chem Neurosci (2013) 0.98
Alzheimer's disease and the amyloid cascade hypothesis: ten years on. Curr Opin Pharmacol (2002) 0.97
Donepezil improves cognitive function in mice by increasing the production of insulin-like growth factor-I in the hippocampus. J Pharmacol Exp Ther (2009) 0.94
Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology (2007) 0.92
The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis. Chem Biol Interact (2008) 0.92
The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int J Geriatr Psychiatry (1999) 0.91
Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. J Alzheimers Dis (2011) 0.91
Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors. Br J Pharmacol (2010) 0.90
Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo. Neurotoxicology (2013) 0.88
Donepezil induces a cholinergic sprouting in basocortical degeneration. J Neurochem (2007) 0.87
Transport of protein-bound steroid hormones into liver in vivo. Am J Physiol (1979) 0.86
Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease. Acta Neurobiol Exp (Wars) (2007) 0.84
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats. Drug Metab Dispos (2010) 0.83
The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats. Neuropsychiatr Dis Treat (2008) 0.82
Induction of expression and functional activity of P-glycoprotein efflux transporter by bioactive plant natural products. Food Chem Toxicol (2011) 0.81
Memantine prevents quinolinic acid-induced hippocampal damage. Eur J Pharmacol (1992) 0.80
Predictors of long-term treatment effect of rivastigmine in Alzheimer's disease: a role for beta-amyloid plasma levels? Neurol Neurochir Pol (2010) 0.79
In vitro investigation of amyloid-β hepatobiliary disposition in sandwich-cultured primary rat hepatocytes. Drug Metab Dispos (2013) 0.78